Phase IIa trial in 264 adults aged 60–85: IVX-A12 RSV/hMPV vaccine (with or without MF59) raised neutralising antibodies (RSV 3–6-fold, hMPV 2–3-fold at day 28) vs placebo; solicited reactions 57.3% and 75.0% vs 37.7%. MF59 added no benefit.
RCTn = 264
Davis et al. A Phase IIa randomized clinical trial of a respiratory syncytial virus and human metapneumovirus combination protein-based virus-like particle vaccine in adults 60-85 years of age